B-intervention	0	6	Weight
I-intervention	7	14	lifting
O	15	18	for
O	19	24	women
O	25	27	at
O	28	32	risk
O	33	36	for
O	37	43	breast
O	44	50	cancer
O	50	51	-
O	51	58	related
B-condition	59	69	lymphedema
O	69	70	:
O	71	72	a
O	73	83	randomized
O	84	89	trial
O	89	90	.

O	91	99	Clinical
O	100	110	guidelines
O	111	114	for
O	115	121	breast
O	122	128	cancer
O	129	138	survivors
O	139	146	without
O	147	157	lymphedema
O	158	164	advise
O	165	172	against
O	173	178	upper
O	179	183	body
O	184	192	exercise
O	192	193	,
O	194	204	preventing
O	205	209	them
O	210	214	from
O	215	224	obtaining
O	225	236	established
O	237	243	health
O	244	252	benefits
O	253	255	of
O	256	262	weight
O	263	270	lifting
O	270	271	.

O	272	274	To
O	275	283	evaluate
O	284	294	lymphedema
O	295	300	onset
O	301	306	after
O	307	308	a
O	309	310	1
O	310	311	-
O	311	315	year
O	316	322	weight
O	323	330	lifting
O	331	343	intervention
O	344	346	vs
B-control	347	349	no
I-control	350	358	exercise
I-control	359	360	(
I-control	360	367	control
I-control	367	368	)
O	369	374	among
O	375	384	survivors
O	385	387	at
O	388	392	risk
O	393	396	for
O	397	403	breast
O	404	410	cancer
O	410	411	-
O	411	418	related
O	419	429	lymphedema
O	430	431	(
O	431	435	BCRL
O	435	436	)
O	436	437	.

O	438	439	A
O	440	450	randomized
O	451	461	controlled
O	462	473	equivalence
O	474	479	trial
O	480	481	(
O	481	489	Physical
O	490	498	Activity
O	499	502	and
O	503	513	Lymphedema
O	514	519	trial
O	519	520	)
O	521	523	in
O	524	527	the
B-location	528	540	Philadelphia
O	541	553	metropolitan
O	554	558	area
O	559	561	of
B-total-participants	562	565	154
B-eligibility	566	572	breast
I-eligibility	573	579	cancer
I-eligibility	580	589	survivors
I-eligibility	590	591	1
I-eligibility	592	594	to
I-eligibility	595	596	5
I-eligibility	597	602	years
I-eligibility	603	617	postunilateral
I-eligibility	618	624	breast
I-eligibility	625	631	cancer
I-eligibility	631	632	,
I-eligibility	633	637	with
I-eligibility	638	640	at
I-eligibility	641	646	least
I-eligibility	647	648	2
I-eligibility	649	654	lymph
I-eligibility	655	660	nodes
I-eligibility	661	668	removed
I-eligibility	669	672	and
I-eligibility	673	680	without
I-eligibility	681	689	clinical
I-eligibility	690	695	signs
I-eligibility	696	698	of
I-eligibility	699	703	BCRL
I-eligibility	704	706	at
I-eligibility	707	712	study
I-eligibility	713	718	entry
O	718	719	.

O	720	732	Participants
O	733	737	were
O	738	747	recruited
O	748	755	between
O	756	763	October
O	764	765	1
O	765	766	,
O	767	771	2005
O	771	772	,
O	773	776	and
O	777	785	February
O	786	790	2007
O	790	791	,
O	792	796	with
O	797	801	data
O	802	812	collection
O	813	819	ending
O	820	822	in
O	823	829	August
O	830	834	2008
O	834	835	.

O	836	842	Weight
O	843	850	lifting
O	851	863	intervention
O	864	872	included
O	873	874	a
O	875	878	gym
O	879	889	membership
O	890	893	and
O	894	896	13
O	897	902	weeks
O	903	905	of
O	906	916	supervised
O	917	928	instruction
O	928	929	,
O	930	934	with
O	935	938	the
O	939	948	remaining
O	949	950	9
O	951	957	months
O	958	970	unsupervised
O	970	971	,
O	972	974	vs
O	975	977	no
O	978	986	exercise
O	986	987	.

O	988	996	Incident
O	997	1001	BCRL
O	1002	1012	determined
O	1013	1015	by
O	1016	1025	increased
O	1026	1029	arm
O	1030	1038	swelling
O	1039	1045	during
O	1046	1048	12
O	1049	1055	months
O	1056	1057	(
O	1057	1058	â
O	1058	1059	‰
O	1059	1060	¥
O	1060	1061	5
O	1061	1062	%
O	1063	1071	increase
O	1072	1074	in
O	1075	1084	interlimb
O	1085	1095	difference
O	1095	1096	)
O	1096	1097	.

O	1098	1107	Clinician
O	1107	1108	-
O	1108	1115	defined
O	1116	1120	BCRL
O	1121	1126	onset
O	1127	1130	was
O	1131	1135	also
O	1136	1145	evaluated
O	1145	1146	.

O	1147	1158	Equivalence
O	1159	1165	margin
O	1166	1169	was
O	1170	1177	defined
O	1178	1180	as
O	1181	1189	doubling
O	1190	1192	of
O	1193	1203	lymphedema
O	1204	1213	incidence
O	1213	1214	.

O	1215	1216	A
O	1217	1222	total
O	1223	1225	of
B-total-participants	1226	1229	134
O	1230	1242	participants
O	1243	1252	completed
O	1253	1259	follow
O	1259	1260	-
O	1260	1262	up
O	1263	1271	measures
O	1272	1274	at
O	1275	1276	1
O	1277	1281	year
O	1281	1282	.

O	1283	1286	The
O	1287	1297	proportion
O	1298	1300	of
O	1301	1306	women
O	1307	1310	who
O	1311	1322	experienced
B-outcome	1323	1331	incident
I-outcome	1332	1336	BCRL
I-outcome	1337	1342	onset
O	1343	1346	was
B-iv-bin-percent	1347	1349	11
I-iv-bin-percent	1349	1350	%
O	1351	1352	(
B-iv-bin-abs	1352	1353	8
O	1354	1356	of
B-intervention-participants	1357	1359	72
O	1359	1360	)
O	1361	1363	in
O	1364	1367	the
O	1368	1374	weight
O	1375	1382	lifting
O	1383	1395	intervention
O	1396	1401	group
O	1402	1405	and
B-cv-bin-percent	1406	1408	17
I-cv-bin-percent	1408	1409	%
O	1410	1411	(
B-cv-bin-abs	1411	1413	13
O	1414	1416	of
B-control-participants	1417	1419	75
O	1419	1420	)
O	1421	1423	in
O	1424	1427	the
O	1428	1435	control
O	1436	1441	group
O	1442	1443	(
O	1443	1453	cumulative
O	1454	1463	incidence
O	1464	1474	difference
O	1475	1476	[
O	1476	1479	CID
O	1479	1480	]
O	1480	1481	,
O	1482	1483	-
O	1483	1484	6
O	1484	1485	.
O	1485	1486	0
O	1486	1487	%
O	1487	1488	;
O	1489	1491	95
O	1491	1492	%
O	1493	1503	confidence
O	1504	1512	interval
O	1513	1514	[
O	1514	1516	CI
O	1516	1517	]
O	1517	1518	,
O	1519	1520	-
O	1520	1522	17
O	1522	1523	.
O	1523	1524	2
O	1524	1525	%
O	1526	1528	to
O	1529	1530	5
O	1530	1531	.
O	1531	1532	2
O	1532	1533	%
O	1533	1534	;
O	1535	1536	P
O	1537	1540	for
O	1541	1552	equivalence
O	1553	1554	=
O	1555	1556	.
O	1556	1558	04
O	1558	1559	)
O	1559	1560	.

O	1561	1566	Among
O	1567	1572	women
O	1573	1577	with
O	1578	1579	5
O	1580	1582	or
O	1583	1587	more
O	1588	1593	lymph
O	1594	1599	nodes
O	1600	1607	removed
O	1607	1608	,
O	1609	1612	the
O	1613	1623	proportion
O	1624	1627	who
O	1628	1639	experienced
B-outcome	1640	1648	incident
I-outcome	1649	1653	BCRL
I-outcome	1654	1659	onset
O	1660	1663	was
B-iv-bin-percent	1664	1665	7
I-iv-bin-percent	1665	1666	%
O	1667	1668	(
B-iv-bin-abs	1668	1669	3
O	1670	1672	of
B-intervention-participants	1673	1675	45
O	1675	1676	)
O	1677	1679	in
O	1680	1683	the
O	1684	1690	weight
O	1691	1698	lifting
O	1699	1711	intervention
O	1712	1717	group
O	1718	1721	and
B-cv-bin-percent	1722	1724	22
I-cv-bin-percent	1724	1725	%
O	1726	1727	(
B-cv-bin-abs	1727	1729	11
O	1730	1732	of
B-control-participants	1733	1735	49
O	1735	1736	)
O	1737	1739	in
O	1740	1743	the
O	1744	1751	control
O	1752	1757	group
O	1758	1759	(
O	1759	1762	CID
O	1762	1763	,
O	1764	1765	-
O	1765	1767	15
O	1767	1768	.
O	1768	1769	0
O	1769	1770	%
O	1770	1771	;
O	1772	1774	95
O	1774	1775	%
O	1776	1778	CI
O	1778	1779	,
O	1780	1781	-
O	1781	1783	18
O	1783	1784	.
O	1784	1785	6
O	1785	1786	%
O	1787	1789	to
O	1790	1791	-
O	1791	1793	11
O	1793	1794	.
O	1794	1795	4
O	1795	1796	%
O	1796	1797	;
O	1798	1799	P
O	1800	1803	for
O	1804	1815	equivalence
O	1816	1817	=
O	1818	1819	.
O	1819	1822	003
O	1822	1823	)
O	1823	1824	.

B-outcome	1825	1834	Clinician
I-outcome	1834	1835	-
I-outcome	1835	1842	defined
I-outcome	1843	1847	BCRL
I-outcome	1848	1853	onset
O	1854	1862	occurred
O	1863	1865	in
B-iv-bin-abs	1866	1867	1
O	1868	1873	woman
O	1874	1876	in
O	1877	1880	the
O	1881	1887	weight
O	1888	1895	lifting
O	1896	1908	intervention
O	1909	1914	group
O	1915	1918	and
B-cv-bin-abs	1919	1920	3
O	1921	1926	women
O	1927	1929	in
O	1930	1933	the
O	1934	1941	control
O	1942	1947	group
O	1948	1949	(
B-iv-bin-percent	1949	1950	1
I-iv-bin-percent	1950	1951	.
I-iv-bin-percent	1951	1952	5
I-iv-bin-percent	1952	1953	%
O	1954	1956	vs
B-cv-bin-percent	1957	1958	4
I-cv-bin-percent	1958	1959	.
I-cv-bin-percent	1959	1960	4
I-cv-bin-percent	1960	1961	%
O	1961	1962	,
O	1963	1964	P
O	1965	1968	for
O	1969	1980	equivalence
O	1981	1982	=
O	1983	1984	.
O	1984	1986	12
O	1986	1987	)
O	1987	1988	.

O	1989	1991	In
O	1992	1998	breast
O	1999	2005	cancer
O	2006	2015	survivors
O	2016	2018	at
O	2019	2023	risk
O	2024	2027	for
O	2028	2038	lymphedema
O	2038	2039	,
O	2040	2041	a
O	2042	2049	program
O	2050	2052	of
O	2053	2059	slowly
O	2060	2071	progressive
O	2072	2078	weight
O	2079	2086	lifting
O	2087	2095	compared
O	2096	2100	with
O	2101	2103	no
O	2104	2112	exercise
O	2113	2116	did
O	2117	2120	not
O	2121	2127	result
O	2128	2130	in
O	2131	2140	increased
O	2141	2150	incidence
O	2151	2153	of
O	2154	2164	lymphedema
O	2164	2165	.
O	2166	2180	clinicaltrials
O	2180	2181	.
O	2181	2184	gov
O	2185	2195	Identifier
O	2195	2196	:
O	2197	2208	NCT00194363
O	2208	2209	.
